1. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status.
Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. The frequency of alternative therapy (prasugrel or ticagrelor) use as maintenance therapy (y axis) in the strata of CYP2C19 intermediate or poor metabolizers (IM/PM) and ultrarapid, rapid, or normal metabolizers (UM/RM/NM) is presented according to the absence (No) and presence (Yes) of the following clinical factors: (A) acute coronary syndrome (ACS) indication for percutaneous coronary intervention (PCI); (B) elevated bleeding risk; (C) left anterior descending (LAD) artery stent placement. The odds ratio (OR; 95% confidence interval [CI]) for the association between presence of the clinical factor with prasugrel/ticagrelor selection within each CYP2C19 phenotype strata (IM/PM or UM/RM/NM), and the CYP2C19 phenotype*clinical factor interaction P value is provided.
Craig R. Lee et al. Circ Genom Precis Med. 2018;11:e002069
Copyright © American Heart Association, Inc. All rights reserved.